Mufg Securities Americas Inc. acquired a new position in Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 28,302 shares of the company's stock, valued at approximately $604,000.
Other hedge funds have also recently bought and sold shares of the company. Malaga Cove Capital LLC acquired a new position in Kenvue in the 4th quarter worth $256,000. Man Group plc bought a new stake in shares of Kenvue in the fourth quarter valued at about $941,000. Nissay Asset Management Corp Japan ADV grew its holdings in shares of Kenvue by 0.6% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 229,272 shares of the company's stock worth $4,936,000 after buying an additional 1,331 shares in the last quarter. NorthRock Partners LLC raised its position in Kenvue by 149.5% in the 4th quarter. NorthRock Partners LLC now owns 29,421 shares of the company's stock valued at $628,000 after buying an additional 17,629 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its stake in Kenvue by 13.1% in the 4th quarter. Nuveen Asset Management LLC now owns 10,360,001 shares of the company's stock valued at $221,186,000 after acquiring an additional 1,198,432 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Kenvue Stock Performance
Shares of KVUE traded down $0.19 during midday trading on Monday, reaching $23.99. 22,179,978 shares of the stock were exchanged, compared to its average volume of 16,516,745. The stock's 50 day simple moving average is $23.16 and its 200 day simple moving average is $22.59. The company has a market cap of $46.03 billion, a P/E ratio of 45.26, a PEG ratio of 2.62 and a beta of 1.02. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17.
Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The firm had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company's revenue was down 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.28 earnings per share. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.42%. Kenvue's dividend payout ratio is 149.09%.
Analyst Ratings Changes
Several brokerages have recently weighed in on KVUE. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Redburn Atlantic assumed coverage on Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target for the company. Finally, UBS Group boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Kenvue has an average rating of "Hold" and an average target price of $25.33.
View Our Latest Research Report on KVUE
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
